FIG 2.

Relative change of driver mutation shed detected in plasma ctDNA. Dot plots comparing change in mutation abundance (copies/mL) of key driver mutations EGFR del19 or L858R, KRAS G12X, or BRAF V600E across consecutive intervals following treatment initiation for the NCI (A) and institutional (C) cohorts. The majority of responses are seen during the initial interval between cycle 1 and 2 for the NCI cohort (B) and between the baseline draw to the first follow-up draw for the institutional clinical cohort (D). ctDNA, circulating tumor DNA, N/D, not defined.